Reviewed by The Peptide Dispatch Editorial Team · Last reviewed July 6, 2026
Dulaglutide (DULA) is a metabolic peptide, at the fda approved stage in the published literature. Dulaglutide (Trulicity) is a long-acting GLP-1 receptor agonist developed by Eli Lilly, approved by the FDA in 2014 for type 2 diabetes. The molecule is a fusion protein consisting of two copies of a modified GLP-1(7-37) analog linked to a modified human IgG4 Fc fragment via a small peptide linker. The REWIND cardiovascular outcomes trial was landmark — it was the first GLP-1 agonist trial to show cardiovascular benefit in a population where most participants did not have established cardiovascular disease.
Dulaglutide (Trulicity) is a long-acting GLP-1 receptor agonist developed by Eli Lilly, approved by the FDA in 2014 for type 2 diabetes. The molecule is a fusion protein consisting of two copies of a modified GLP-1(7-37) analog linked to a modified human IgG4 Fc fragment via a small peptide linker. The REWIND cardiovascular outcomes trial was landmark — it was the first GLP-1 agonist trial to show cardiovascular benefit in a population where most participants did not have established cardiovascular disease.
| Research Status | FDA Approved |
|---|---|
| Half-Life | ~5 days |
| Administration | Subcutaneous injection |
| Doses Reported in Published Studies | 0.75-4.5 mg once weekly |
| Molecular Weight | ~63,000 Da (fusion protein) |
Dulaglutide activates GLP-1 receptors to enhance glucose-dependent insulin secretion, suppress glucagon release, slow gastric emptying, and reduce appetite. The Fc fragment provides extended half-life through FcRn-mediated recycling and reduced renal clearance.
Dulaglutide (Trulicity) is a long-acting GLP-1 receptor agonist developed by Eli Lilly, approved by the FDA in 2014 for type 2 diabetes. The molecule is a fusion protein consisting of two copies of a modified GLP-1(7-37) analog linked to a modified human IgG4 Fc fragment via a small peptide linker. The REWIND…
Dulaglutide activates GLP-1 receptors to enhance glucose-dependent insulin secretion, suppress glucagon release, slow gastric emptying, and reduce appetite. The Fc fragment provides extended half-life through FcRn-mediated recycling and reduced renal clearance.
Dulaglutide is at the following stage in the published literature: FDA Approved. All information is for research and educational purposes only.
Reported half-life: ~5 days.
Reported administration route in the literature: Subcutaneous injection. This is not a recommendation for human use.
Educational content, not medical advice. Effects described are drawn from cited research in study subjects.